Business / Health

Add as a preferred source on Google

Radnostix Third-Quarter Loss Widens to $842,242 as Revenue Falls

Theranostics sales rose 15%, but delayed cobalt contracts and weaker calibration product sales weighed on results.

Updated 2 min read
A worker handles a shielded isotope container at a facility in Idaho Falls, Idaho. (AI-generated image / EconoTimes)
A worker handles a shielded isotope container at a facility in Idaho Falls, Idaho. (AI-generated image / EconoTimes)

Radnostix Inc. reported a wider third-quarter loss after a sharp decline in cobalt sales, as stronger theranostics demand failed to offset delayed contracts and a supply interruption affecting its results.

Revenue fell 22% to $2.57 million in the three months ended Sept. 30, from $3.28 million a year earlier. The net loss widened to $842,242 from $203,601, the company reported Nov. 16. For the first nine months of 2026, revenue fell to $7.62 million from $10.17 million, while the net loss reached $3.07 million, compared with $477,080.

Quarterly cobalt sales dropped to $90,680 from $766,682. Radnostix said large contracts have been delayed while amendments to its registered sealed-source devices await action by the U.S. Nuclear Regulatory Commission (NRC).

Calibration and reference product sales declined to $737,222 from $961,093. The company estimated that an interruption in cobalt-57 supply reduced third-quarter sales by about $250,000. It also reported a cobalt-57 shortage in 2024 that was followed by catch-up sales in 2025.

Theranostics sales rose 15% to $1.71 million for the quarter. Radnostix said customer volumes recovered in July after two voluntary recalls earlier in 2026, though sales for the first nine months remained 19% below the year-earlier period at $4.18 million.

Cash and equivalents stood at $711,288 on Sept. 30, down from $1.70 million at the end of 2025. Radnostix entered a $1 million revolving credit agreement in October. It has also agreed to sell assets tied to its fluorine business and a planned depleted uranium facility to HALEU Energy Fuel Inc., a subsidiary of Nano Nuclear Energy Inc.

The conditional sale is valued at $13.5 million, including $9.5 million in cash and $4 million in restricted Nano Nuclear shares. Radnostix said $500,000 was released to it from escrow in October. Up to an additional $9 million in cash, less any payments to release liens, is due at closing. Conditions include NRC approval of a license transfer and the buyer obtaining rights to the project site.

Radnostix also said it submitted a Type II Drug Master File to the U.S. Food and Drug Administration (FDA) in October for Sodium Iodide I-131 active pharmaceutical ingredient to support a customer’s drug application. FDA does not approve Drug Master Files separately; it assesses their contents when reviewing applications that cite them.

Radnostix expects to execute the delayed cobalt contracts in the first quarter of 2027, subject to the NRC amendments.

Related articles

View all